# Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Study · id `cardio:ct-nct03397121` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03397121](<https://clinicaltrials.gov/study/NCT03397121>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03397121

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.

## Technical summary

Registry record NCT03397121. Randomized; double masking; primary purpose treatment. Start 2017-11-28 (actual); primary completion 2019-08-27 (actual). Results posted on 2020-10-28.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 482 participants (enrolled count; ClinicalTrials.gov record NCT03397121, source copy `cardio:ctgov-nct03397121-2020-10-28`, retrieved 2026-10-31)
- Started: 2017-11-28 (actual) (ClinicalTrials.gov record NCT03397121, source copy `cardio:ctgov-nct03397121-2020-10-28`, retrieved 2026-10-31)
- Primary completion: 2019-08-27 (actual) (ClinicalTrials.gov record NCT03397121, source copy `cardio:ctgov-nct03397121-2020-10-28`, retrieved 2026-10-31)
- Completion: 2019-09-17 (actual) (ClinicalTrials.gov record NCT03397121, source copy `cardio:ctgov-nct03397121-2020-10-28`, retrieved 2026-10-31)
- Results first posted: 2020-10-28 (ClinicalTrials.gov record NCT03397121, source copy `cardio:ctgov-nct03397121-2020-10-28`, retrieved 2026-10-31)
- Countries: United States; Canada; Czechia; Denmark; Netherlands; South Africa; Spain; Sweden (ClinicalTrials.gov record NCT03397121, source copy `cardio:ctgov-nct03397121-2020-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03397121-2020-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
- Acronym: ORION-9
- Condition: Heterozygous Familial Hypercholesterolemia
- Condition: Elevated Cholesterol
- Intervention (Drug): Inclisiran
- Intervention (Drug): Placebo
- Lead sponsor: The Medicines Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: The Medicines Company (`cardio:org-the-medicines-company`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia (`cardio:pubmed-32197277`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c6ab3774e2b3d16df83fdc0977f0469a2b6dd9bacf0d78fe3357703ff4654215
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
